Live
- World Heritage Week celebrations conclude
- Coronation of Vishvaraj as Mewar’s 77th successor starts amid questions over palace visit
- Give utmost priority to research: SKLTHU V-C
- IT Min launches ‘Transforming 10,000 Minds’ prog
- TTD Board member interacts with locals in Tirumala
- Uttam prods babus to fast-track irrigation projects across State
- Union minister Pradhan launches 'The Teacher App'
- Oppn members seek more time for JPC on Waqf Bill
- SC upholds ‘secular, socialist’ in Preamble
- RASS conducts Siva Parvathi Kalyanam
Over half of COVID-19 infected adults in South Africa are asymptomatic: Official
Covid-19 patients are being treated at the Tshwane District Hospital in Pretoria, South Africa, Friday July 10, 2020. (Photo | AP)
The coronavirus, which first emerged in China's Wuhan city, has claimed 3,860 lives in South Africa with over 2,50,000 confirmed cases.
Johannesburg: A top health official in South Africa has said that about 50 to 66 per cent of all the adults infected with the COVID-19 disease in the country are asymptomatic, with many infections going undetected.
The coronavirus, which first emerged in China's Wuhan city, has claimed 3,860 lives in South Africa with over 2,50,000 confirmed cases.
"The majority of COVID-19 infections are going unnoticed," according to Dr Shabir Madhi, the leader of the South African leg of an international vaccine trial headed by the University of Oxford.
In an interview with CNBC on Friday, Madhi said the high number of asymptomatic cases was causing difficulties in vaccine trials.
The enrolment process has shown that far more people are asymptomatic than what was previously believed, he said.
He estimated that only about 10 per cent of all COVID-19 cases are being officially reported.
Madhi said around 80 per cent of all children who are infected are asymptomatic.
The clinical trials require people who have not been infected by the virus.
Part of the enrolment process for the COVID-19 vaccine trial involves the screening of individuals.
Qualifying participants are randomly allocated into one of two groups -- vaccine group or placebo group.
Madhi said the results on whether the vaccine works as a protection against COVID-19 would be available by the end of November this year, but the trials may be extended into the second quarter of next year.
He warned against 'undue' optimism, reminding that only 10 per cent of vaccines that go into clinical trials are eventually licensed for use.
"Right now there are approximately 200 vaccines that are being developed (around the world) for COVID-19.
"It would be a huge accomplishment if, over the next 12 to 18 months, we are successful in showing that even one out of every 20 of the vaccines that go into human studies are safe and provide some protection against COVID-19," Madhi said.
He said that for the next year at least, the only reliable protection against the COVID-19 would be the non-pharmaceutical interventions of handwashing, sanitisation and social distancing.
